Relationship of Glycated Hemoglobin A1c with All-Cause and Cardiovascular Mortality among Patients with Hypertension
Open Access
- 30 March 2023
- journal article
- research article
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 12 (7) , 2615
Abstract
Both low and high glycated hemoglobin A1c (HbA1c) levels are well-established causal risk factors for all-cause and cardiovascular mortality in the general population and diabetic patients. However, the relationship between HbA1c with all-cause and cardiovascular mortality among patients with hypertension is unclear. We used NHANES data from 1999 to 2014 as the basis for this population-based cohort study. Based on HbA1c levels (HbA1c > 5, HbA1c > 5.5, HbA1c > 6, HbA1c > 6.5, HbA1c > 7%), hypertensive patients were divided into five groups. An analysis of multivariable Cox proportional hazards was conducted based on hazard ratios (HRs) and respective 95% confidence intervals (CIs). The relationship between HbA1c and mortality was further explored using Kaplan–Meier survival curves, restricted cubic spline curves, and subgroup analyses. In addition, 13,508 patients with hypertension (average age 58.55 ± 15.56 years) were included in the present analysis, with 3760 (27.84%) all-cause deaths during a follow-up of 127.69 ± 57.9 months. A U-shaped relationship was found between HbA1c and all-cause and cardiovascular mortality (all p for likelihood ratio tests were 0.0001). The threshold value of HbA1c related to the lowest risk for all-cause and cardiovascular mortality was 5.3% and 5.7%, respectively. Below the threshold value, increased HbA1c levels reduced the risk of all-cause mortality (HR 0.68, 95% CI 0.51–0.90, p = 0.0078) and cardiovascular mortality (HR 0.77, 95% CI 0.57–1.05, p = 0.0969). Inversely, above the threshold value, increased HbA1c levels accelerated the risk of all-cause mortality (HR 1.14, 95% CI 1.11–1.18, p < 0.0001) and cardiovascular mortality (HR 1.22, 95% CI 1.16–1.29, p < 0.0001). In conclusion, A U-shape relationship was observed between HbA1c and all-cause and cardiovascular mortality among hypertensive patients.Keywords
Funding Information
- National Natural Scientific Foundation (82004135, ZY2022KY03, YN10101915)
- Research Fund for Zhaoyang Talents of Guangdong Provincial Hospital of Chinese Medicine (82004135, ZY2022KY03, YN10101915)
- Specific Research Fund for TCM Science and Technology of Guangzhou Provincial Hospital of Chinese Medicine (82004135, ZY2022KY03, YN10101915)
This publication has 30 references indexed in Scilit:
- HbA1c and the Risks for All-Cause and Cardiovascular Mortality in the General Japanese PopulationDiabetes Care, 2013
- Relationship between HbA1c levels and risk of cardiovascular adverse outcomes and all-cause mortality in overweight and obese cardiovascular high-risk women and men with type 2 diabetesDiabetologia, 2012
- Hypoglycemia and Cardiovascular RisksDiabetes Care, 2011
- Elevated glycated haemoglobin is a strong predictor of mortality in patients with left ventricular systolic dysfunction who are not receiving treatment for diabetes mellitusHeart, 2009
- A New Zealand Linkage Study Examining the Associations Between A1C Concentration and MortalityDiabetes Care, 2008
- Vascular disease and diabetes: is hypoglycaemia an aggravating factor?Diabetes/Metabolism Research and Reviews, 2008
- Glycosylated Hemoglobin and Mortality in Patients with Nondiabetic Chronic Kidney DiseaseJournal of the American Society of Nephrology, 2005
- Diabetes, hyperglycaemia and mortality in disabled older women: The Women's Health and Ageing Study IDiabetic Medicine, 2005
- Reverse epidemiology of conventional cardiovascular risk factors in patients with chronic heart failureJACC, 2004
- Diabetes and Vascular DiseaseCirculation, 2003